Therapeutic strategies targeting upstream obesity-related inflammation, through weight loss, anti-inflammatory agents, or insulin-sensitizing drugs, may offer dual benefits by attenuating both amyloid and tau progression, thus slowing or preventing AD trajectory. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.